PTHS
AMEX · Biotechnology

Pelthos Therapeutics Inc

$21.68
+0.43 (+2.02%)
As of Sep 29, 3:20 PM ET ·
Financial Highlights (FY 2026)
Revenue
34.52M
Net Income
-89,026,856
Gross Margin
76.2%
Profit Margin
-257.9%
Rev Growth
—
D/E Ratio
0.81
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 76.2% 34.6% 34.6% 34.6%
Operating Margin -194.8% 15.6% 18.3% 16.9%
Profit Margin -257.9% 13.7% 13.1% 13.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 34.52M 12.22M 12.16M 13.52M
Gross Profit 26.32M 4.22M 4.20M 4.67M
Operating Income -67,233,768 1.91M 2.23M 2.28M
Net Income -89,026,856 1.67M 1.59M 1.78M
Gross Margin 76.2% 34.6% 34.6% 34.6%
Operating Margin -194.8% 15.6% 18.3% 16.9%
Profit Margin -257.9% 13.7% 13.1% 13.2%
Rev Growth — +12.4% +20.7% +15.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 19.17M 35.24M 30.53M 34.79M
Total Equity 23.71M 56.05M 48.64M 50.50M
D/E Ratio 0.81 0.63 0.63 0.69
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -64,036,156 2.79M 3.00M 3.51M
Free Cash Flow — 1.30M 1.27M 1.44M